The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables (hass)

Regional Hospital Holstebro

Status: Completed

Conditions: Essential Hypertension

Treatments: Drug: Amiloride; Other: Placebo; Drug: Spironolactone

Study type: Interventional

Funder types: Other

Identifiers

NCT01195805

MED.RES.HOS.2010.03.SKM

Details and patient eligibility

About

The investigators wish to study the effect of retaining potassium. The participants have essential hypertension. The test substances are Amiloride, Spironolactone and placebo. The participants will ingest tablets for 28 days before being examined. We will perform a 24 hours urine collection, 24-hours bloodpressure measurement, blood and urine samples and we also examine the patient using a SphygmoCor.

Full description

Purpose of the study is to examine the effect of amiloride and spironolactone on

1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK),
2. Pulsewave velocity, augmentation index central bloodpressure,
3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and
4. Ambulatory bloodpressure

Enrollment: 25 estimated patients

Sex: All

Ages: 40 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• hypertension,
• BMI 18,5-30,
• non-smoker

Exclusion criteria

• Smoking
• Not using contraceptives
• Other illnesses
• Drug or alcohol abuse

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

25 participants in 3 patient groups, including a placebo group

Amiloride

Active Comparator group

Treatment:

Drug: Amiloride

Spironolactone

Active Comparator group

Treatment:

Drug: Spironolactone

Placebo

Placebo Comparator group

Description:

1 tablet twice a day for 28 days

Treatment:

Other: Placebo